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The aim of this study was to evaluate the eﬀect of curcumin on morphine tolerance and the corresponding cytokine/chemokine
changes. Male ICR mice were made tolerant to morphine by daily subcutaneous injection for 7 days. Intraperitoneal injections
of vehicle, low-dose or high-dose curcumin were administered 15min after morphine injection, either acutely or chronically
for 7 days to test the eﬀect of curcumin on morphine-induced antinociception and development of morphine tolerance. On
day 8, cumulative dose-response curves were generated and the 50% of maximal analgesic dose values were calculated and
compared among groups. Corresponding set of mice were used for analyzing the cytokine responses by antibody-based cytokine
proteinarray.Acute,high-dosecurcuminenhancedmorphine-inducedantinociception.Whilemorphinetolerancewasattenuated
by administration of low-dose curcumin following morphine injections for 7 days, it was aggravated by chronic high-dose
curcumin following morphine injection, suggesting a biphasic eﬀect of curcumin on morphine-induced tolerance. Of the 96
cytokine/chemokinesanalyzedbymousecytokine protein array,14cytokinesexhibited signiﬁcantchangesafter thediﬀerent 7-day
treatments. Mechanisms for the modulatory eﬀects of low-dose and high-dose curcumin on morphine tolerance were discussed.
Even though curcumin itself is a neuroprotectant and low doses of the compound serve to attenuate morphine tolerance, high-
doses of curcumin might cause neurotoxicity and aggravate morphine tolerance by inhibiting the expression of antiapoptotic
cytokines and neuroprotective factors. Our results indicate that the eﬀect of curcumin on morphine tolerance may be biphasic,
and therefore curcumin should be used cautiously.
1.Introduction
While opioids are the drug of choice for the alleviation of
acute and chronic pain, opioid tolerance, which refers to the
diminution of the analgesic eﬀect or the need for a higher
dose to maintain the original eﬀect after chronic opioid
exposure, remains a perpetual concern, especially since
the mechanisms underlying the development of tolerance
are complex and still unclear [1]. Recent studies indicate
that repeated morphine exposure progressively activates the
spinal cord glia, resident immune cells of the central nervous
system (CNS), resulting in the release of proinﬂammatory
cytokines that trigger nitric oxide and p38 mitogen-activated
proteinkinase and lead totheblockingofmorphine-induced2 Evidence-Based Complementary and Alternative Medicine
a n t i n o c i c e p t i o ni nt o l e r a n ts u b j e c t s[ 2]. Gene therapy for
the release of anti-inﬂammatory cytokines also potentiates
acute,morphine-induced antinociception and attenuates the
development of morphine tolerance [3]. Furthermore, the
use of neutralizing antibodies against chemokine recep-
tors modulates the antinociceptive eﬀect of morphine and
reduces morphine tolerance [3]. These observations suggest
that the actions of cytokines/chemokines could play a key
role in the development of morphine tolerance.
Curcumin (diferuloylmethane) is a yellow-colored phe-
nolic pigment, the active constituent of Curcuma longa,a n d
is extensively used as a spice as well as a food preservation
and coloringmaterial in India, China and SoutheastAsia [4].
Several therapeutic eﬀects of curcumin have been reported
[5], including the ability to attenuate diabetic neuropathic
pain through a dose-dependent inhibition of the release
of proinﬂammatory cytokines [6, 7]. While neuropathic
pain and morphine tolerance are two seemingly unrelated
phenomena, they share a common central neuroplastic
pathway [8]. Furthermore, drugs for neuropathic pain and
opioidtolerancearepossiblyinterchangeableinsomeaspects
and the biochemical alterations observed in opioid tolerance
might also be found in neuropathic pain [9]. An oral
low-dose curcumin treatment of 10−100mgkg−1 taken 1h
before morphine administration once daily for 5 consecutive
days resulted in a dose-dependent reduction of morphine
toleranceandthedisappearanceoftheupregulationofbrain-
derived neurotrophic factor, an anti-opioid substance [10].
However,the eﬀectofhigh-dosecurcuminanditsinteraction
with cytokine/chemokine production have not yet been
examinedwithregardtomorphinetolerance.Anotherreport
showed that the intraperitoneal (i.p.) administration of
curcumin produced a dose-dependent inhibition of facial
grooming in both acute and tonic phases in rats with
formalin-induced orofacial pain, and high-dose curcumin
(400 and 600mgkg−1) exhibited the greatest suppressive
eﬀect [11]. Using this dosage, we investigated whether high-
dose curcumin also attenuates morphine tolerance in the
same dose-dependent manner. The excellent tolerance of
curcumin as a food additive with minimal side eﬀects was
observed when high doses were taken by healthy volunteers
[12]. However, the typical expression of hormesis, the
biphasic dose response, of curcumin has been reported
[13]. Furthermore, some of the eﬀects of curcumin at high
doses in vitro are clearly toxic and undesirable beyond
its use in cancer therapy [14]. Therefore, the purpose
of this investigation was to evaluate the dose eﬀects of
curcumin on morphine tolerance and the corresponding
cytokine/chemokine responses.
2.Methods
2.1. Animals. Male ICR mice in the weight range of 18−22
g were used in all experiments. The mice were housed in
a room with a 12-h light/dark cycle and given free access
to a laboratory standard-fat diet and tap water. The use of
animals in this study conformed to the Guiding Principles in
the Care and Use of Animals as approved by the Council of
the American Physiology Society and by the Taipei Medical
University.
2.2. Drugs and Injection Methods. All of the mice received
100μL injections. Morphine hydrochloride (morphine-HCl)
was dissolved in physiological saline and injected subcu-
taneously (s.c.), whereas curcumin (Sigma Co., St Louis,
Missouri, USA) was dissolved in 70% dimethyl sulfoxide
(DMSO) and injected i.p. The chemical structures of mor-
phine and curcumin are shown in Figure 1.O nt h eb a s i s
of the cumulative evidences of discrepancies in the eﬀects
of curcumin, we chose the i.p. route for its administration.
Since DMSO can alter morphine antinociception after both
acute (enhancement) and chronic (inhibition) administra-
tions depending on its concentration [15], we also examined
the eﬀect of DMSO on morphine antinociception using the
following study design.
2.3. Antinociceptive Test, Induction of Morphine Tolerance
and Body Weight Measurement. Tail-ﬂick latency in the hot-
water immersion test (52◦C ± 0.1◦C) was measured to assess
the antinociceptive eﬀect and the development of tolerance
in mice receiving a morphine injection either alone or in
combination with a low or high dose of curcumin. Before
each test, the mice were placed in a plastic restrainer for
30min to acclimatize. A maximum hot water exposure (cut-
oﬀ) time of 10 s was used to avoid tissue damage. Previous
studies have shown that morphine-HCl (10mgkg−1, s.c.)
exhibits its maximal analgesic eﬀect—from 15 to 60min
after administration [10] and plasma concentrations of
curcumin reach their maximum concentrations 15min after
i.p. administration [16]. Therefore, the mice were ﬁrst
treated with morphine-HCl (10mgkg−1, s.c.), then treated
with DMSO or curcumin (25 or 400mgkg−1, i.p.) and
evaluatedin thetail-ﬂicktest15min after injection ofDMSO
or curcumin. To study the acute eﬀects of DMSO and
curcumin (25 or 400mgkg−1, i.p.) on the antinociceptive
eﬀect of morphine (1mgkg−1, s.c.), tail-ﬂick tests were
conductedevery15minaftertheﬁnaldruginjectionfora90-
min period. In experiments exploring the eﬀect of chronic
curcumin treatment on the development of morphine
tolerance, mice were given morphine-HCl (10mgkg−1, s.c.)
followed 15min later by DMSO (100μL, i.p.) or curcumin
(25 or 400mgkg−1, i.p.) daily for 7 days. To determine the
cumulative dose-response curve on Day 8, tail-ﬂick latencies
were converted into maximum percent eﬀect (MPE) using
the equation:
MPE(%)
=
Test response time − Basalresponsetime
Cut-off time −Basalresponse time
× 100.
(1)
Immediately after the baseline latency assessment, mice
were injected s.c. every 30min with a set of progressively
increasing morphine doses, each of which doubled the
concentration of the preceding one (e.g., 5, 10, 20, 40,
80, 160 and 320mgkg−1). Tail-ﬂick latencies were tested
30min after each dose and the subsequent dose was injectedEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Chemical structures of curcumin (a) and morphine hydrochloride (b).
immediately. The progressive dosing procedure continued
until the mice did not move their tails within the 10 s
cutoﬀ time. To investigate trends in body weight changes
during the administration of various drugs, a set of mice
were divided into four groups—NS-NS group, normal saline
(NS) (100μL, s.c.) followed by NS (100μL, i.p.); Mo-NS
group, morphine (10mgkg−1, s.c.) followed by NS (100μL,
i.p.); Mo-25 Curgroup, morphine (10mgkg−1,s.c.)followed
by low-dose curcumin (25mgkg−1, i.p.) and Mo-400 Cur
group, morphine (10mgkg−1, s.c.) followed by high-dose
curcumin (400mgkg−1, i.p.), and were compared on Day 1
and Day 8.
2.4. Semi-Quantitative Cytokine/Chemokine Protein Array.
Bloodsamples were collected via the mandibular artery from
a new set of mice on Day 8 from the NS-NS,Mo-NS, Mo-25
and Mo-400 Cur groups. The time interval between the two
treatments was15min. Forthe bloodcollection, each sample
contained200μLofbloodand10μLofanticoagulant.There-
after, the sample was immediately centrifuged at 1300 g for
20min at 4◦C and the supernatant was stored at −80◦Cu n t i l
analysis. Each protein array required 300μLf o ra d e q u a t e
detection, with equal volumetric contributions from each
mouse within the group (e.g., 75μLf r o me a c hm o u s ei na
group of four or 60μL from each mouse in a group of ﬁve).
Cytokineexpression was detectedbyusingtheRayBioMouse
Cytokine Antibody Array C Series 1000, which combines the
mouse cytokineantibody array 3 (consisting of62cytokines)
and 4 (consisting of 34 cytokines) to detect the expression
of 96 cytokine expression in one experiment. All procedures
wereperformed accordingtothemanufacturer’s instructions
(RayBiotech,Inc., USA)and the signal intensity was scanned
and quantiﬁed by densitometry. Positive control signals were
generated with biotin-conjugated immunoglobulin G (IgG)
antibodies, which are used to identify the orientation of and
compare the relative expression levels among the diﬀerent
membranes. Changes in intensity ratio were considered
signiﬁcant if they satisﬁed either one of the following
conditions: (i) the changes doubled or decreased by half or
(ii) the intensity ratio became undetectable or vice versa.
2.5. Statistical Analysis. All data were expressed as the mean
± standard error (SE). SigmaPlot 10.0 was used to plot the
cumulative dose-response curve. We used a linear regression
m o d e li nt h eS t a t i s t i c a lP a c k a g ef o rS o c i a lS c i e n c e sv e r s i o n
10 (SPSS 10.0) to predict the 50% of maximal analgesic
dose (AD50) and to subsequently generate corresponding
95% conﬁdence intervals (CI). Tail-ﬂick latencies for the
same time periods within groups were compared by one-way
analysis ofvariance (ANOVA)testsand posthoc comparisons
between groups were performed using Duncan’s test. A
paired t-test was used to detect the trend of tail-ﬂick latency
withinthesamegroupatdiﬀerenttimepoints.P-values<.05
were considered statistically signiﬁcant.
3.Results
3.1. Inhibition of Body Weight Gain by Chronic Morphine
and/or High-Dose Curcumin Administration. We observed
diﬀerences in body weight gain between the groups during
the course of drug injection. As shown in Figure 2,b o d y
weight on Day 1 was not signiﬁcantly diﬀerent between the
groups. Chronic administration of morphine (10mgkg−1,
s.c.) alone or in combination with low-dose curcumin
(25mgkg−1, i.p.) for 7 days resulted in an increased body
weight on Day 8 when compared with each mouse’s own
baseline on Day 1. However, the observed body weight gain
in the three study groups was still less than the gain seen
in the control (NS-NS) group. No signiﬁcant diﬀerence in
weight gain was found between the morphine with low-dose
curcumin (Mo-25 Cur) group and the morphine followed
by NS (Mo-NS) group. However, chronic daily injection of
high-dose curcumin after morphine administration further
decreasedthebody weightgain comparedwiththemorphine
plus vehicle (Mo-NS) group.
3.2. Enhancement of Morphine’s Antinociception by Acute
High-dose Curcumin Injection. To see if the acute injec-
tion of DMSO or curcumin could enhance morphine’s
antinociception, we ﬁrst examined if there was an intrinsic
antinociceptive eﬀect exerted by DMSO (100μL, i.p.), low-,
or high-dose curcumin. These drugs were injected i.p.
15min after normal saline injection (100μL, s.c.), and
we observed no antinociceptive eﬀe c ti nc o m p a r i s o nw i t h
the NS-NS control group (data not shown). Second, a
submaximal dose of morphine (1mgkg−1, s.c.) was injected,
followed by DMSO, and a low- or high-dose curcumin
injection 15min later, to examine if these agents could
enhance morphine’s antinociception (Figure 3). Tail-ﬂick
latency testing applied 15min after the administration of4 Evidence-Based Complementary and Alternative Medicine
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Figure 2:Eﬀect of chronicmorphineand/or curcumin administra-
tion on body weight after a 7-day injection. Formulas of injection
on each day, including NS-NS, Mo-NS, Mo-25 Cur and Mo-400
Cur, represent normal saline (100μL, s.c.) followed by normal
saline(100μL,i.p.),morphine(10mgkg−1,s.c.)followedbynormal
saline (100μL, i.p.), morphine (10mgkg−1, s.c.) followed by low-
dose curcumin (25mgkg−1, i.p.), and morphine (10mgkg−1, s.c.)
followed by high-dose curcumin (400mgkg−1, i.p.) respectively.
The interval between injections for each group was 15min.
￿P <
.001, = .005, = .021, diﬀerent from their own baseline body weight
onDay1intheNS-NS,Mo-NSandMo-25Curgroups,respectively.
￿P <.05comparedwithNS-NSgroup. #P <.05comparedwithMo-
NS group. &P < .05 compared with Mo-25 Cur group.
the last drug demonstrated that all four drug combinations
(morphine (1mgkg−1, s.c.) followed 15min later by normal
saline (M1-NS), DMSO (M1-DMSO) and a low-dose (M1-
25 Cur) or high-dose curcumin (M1-400 Cur)) yielded a
signiﬁcant antinociceptive eﬀect when compared with the
control (NS-NS) group within 15−60min of the morphine
injection, and this eﬀect declined thereafter. Noticeably,
high-dose curcumin enhanced morphine’s antinociceptive
capabilities when compared with other treatments; however,
the enhancement only occurred 15min after the last drug
injection in M1-400 Cur group (Figure 3).
3.3. Curcumin on the Development of Morphine Tolerance.
Figure 4 demonstrates that administration of morphine
s.c. at a dose of 10mgkg−1 per day resulted in morphine
tolerance on Day 2, and this tolerance was increasingly
apparent in the following days. Low-dose curcumin attenu-
ated the development of morphine tolerance from days 2 to
7. Conversely, high-dose curcumin only retained morphine’s
antinociception from days 2 to 4, with the eﬀect diminishing
from days 5 to 7.
3.4. Low-dose Curcumin Attenuated but High-dose Curcumin
Worsened Morphine Tolerance after 7 Days Morphine Co-
injection. On Day 8, we plotted cumulative dose−response
curves (Figure 5) and AD50 values for morphine were
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Figure3:Acutetail-ﬂickresponsestodrugcombinations.Formulas
of injection, including NS-NS, M1-NS, M1-DMSO, M1-25 Cur
and M1-400 Cur, represent normal saline (100μL, s.c.) followed by
normal saline (100μL, i.p.), morphine (1mgkg−1, s.c.) followed by
normal saline (100μL, i.p.), morphine (1mgkg−1, s.c.) followed by
DMSO (100μL, i.p.), morphine (1mgkg−1, s.c.) followed by low-
dose curcumin (25mgkg−1, i.p.) and morphine (1mgkg−1, s.c.)
followed by high-dose curcumin (400mgkg−1, i.p.), respectively.
The interval between injections for each group was 15min. #P <
.05 compared with M1-NS group. &P < .05 compared with M1-
DMSO group.
￿P < .05 < compared with M1-25 Cur group.
￿P
< .05 compared with NS-NS group.
Table 1: Eﬀects of DMSO and curcumin on the development of
morphine tolerance.
Chronic treatment AD50 (mg kg−1) 95% CI
Morphine-Normal saline 28.0 21.5–34.5
Morphine-DMSO 29.5 20.0–39.0
Morphine-25mgkg−1 Curcumin 13.0 7.63–18.5
Morphine-400mgkg−1 Curcumin 98.1 73.2–122
After 7 days of chronic treatment period, cumulative dose-response curves
to acute morphine were generated on Day 8. AD50 were derived from these
curves in Figure 5 CI represents conﬁdence interval.
determined as previously described (Table 1). The AD50
value for morphine was 28mgkg−1 in morphine-tolerant
mice. The 95% CI for the AD50 value of morphine-tolerant
mice with normal saline or DMSO injections overlapped,
resulting in an insigniﬁcant shift of the dose-response curve.
Chronic daily morphine injection followed by low-dose
curcuminenhancedtheantinociceptiveeﬀectofmorphinein
tolerant mice, with an AD50 of 13.0mgkg−1 and a 2.15-fold
shift in the dose-response curve. On the other hand, chronic
daily morphine injection followed by high-dose curcumin
signiﬁcantly worsened morphine tolerance, with an AD50
of 98.1mgkg−1 and a 3.5-fold shift in the dose-response
curve.Evidence-Based Complementary and Alternative Medicine 5
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Figure 4: Tail-ﬂick responses to chronic drug combinations for 7
days. Formulas of drug injections, including Mo-NS, Mo-DMSO,
Mo-25 Cur and Mo-400 Cur, represent morphine (10mgkg−1, s.c.)
followed by normal saline (100μL, i.p.), morphine (10mgkg−1,
s.c.) followed by DMSO (100μL, i.p.), morphine (10mgkg−1, s.c.)
followed by low-dose curcumin (25mgkg−1, i.p.) and high-dose
curcumin (400mgkg−1, i.p.), respectively, on each day. The interval
between injections in each group was 15min. Within the Mo-NS
group, #P = .005 and &P < .001 versus Day 1. For Mo-25 Cur group,
￿P < .05 compared with Mo-NS at each time; whereas for Mo-400
Cur group,
￿P < .05 compared with Mo-NS at each time.
0
20
40
60
80
100
120
M
P
E
(
%
)
1 10 100 1000
Morphine (mg/kg)
Mo-NS (n = 9)
Mo-DMSO (n = 4)
Mo-25 Cur (n = 5)
Mo-400 Cur (n = 4)
Figure 5: Cumulative dose-response curve on Day 8. Formulas of
drug injections,includingMo-NS,Mo-DMSO,Mo-25Cur andMo-
400 Cur, indicate morphine (10mgkg−1, s.c.) followed by normal
saline(100μL,i.p.),morphine(10mgkg−1,s.c.)followedby DMSO
(100μL, i.p.), morphine (10mgkg−1, s.c.) followed by low-dose
curcumin (25mgkg−1, i.p.) and high-dose curcumin (400mgkg−1,
i.p.), respectively, for7 days. The interval between injections in each
group was 15min.
3.5. Low- and High-dose Curcumin on the Expression
of Cytokines/chemokines in the Development of Morphine
Tolerance in Mice. In order to investigate the role of
cytokines/chemokines in the development of morphine
toleranceinmice,bothwithandwithoutcurcumininjection,
up to 96 cytokines/chemokines were examined on Day 8
after injections for seven consecutive days. Even though
no result reached a 2-fold increase or decrease against
controls, 14 cytokines/chemokines appeared or disappeared
after intervention and were therefore viewed as signiﬁcant.
When compared with the NS-NS group, s.c. morphine
injection for 7 days eliminated the expression of fms-
like tyrosine kinase 3 ligand (Flt3-ligand), macrophage-
derived cytokine (MDC) and vascular endothelial growth
factor (VEGF), whereas chronic daily morphine injection
followed by low-dose curcumin restored the expressions
of three proteins (Table 2). Compared with the Mo-NS
group, injection of morphine with high-dose curcumin
further eliminated the expression of a few more proteins,
including leptin, VEGF receptor 1 (VEGFR-1), stem cell
factor (SCF), regulated on activation, normal T expressed
and secreted (RANTES),macrophageinﬂammatory protein-
1α (MIP-1α), macrophage inﬂammatory protein-3α (MIP-
3α), interleukin-13 (IL-13), cytokine-response gene 2 (CRG-
2), soluble tumor necrosis factor receptor type II (sTNFRII)
and tumor necrosis factor α (TNFα). In both low- and
high-dose conditions, eotaxin was expressed in response to
curcumin injection.
4.Discussion
In this study, we used a mouse model of morphine tolerance
to measure body weight change, tail-ﬂick latency and
serum cytokine/chemokine expression. Morphine tolerance
reduced body weight gain. For high-dose curcumin injec-
tion (Mo-400 Cur group in Figure 2), the body weight
gain was reduced even further. Although previous studies
reported a possible confounding eﬀect of DMSO when
used as a solvent [15], our results revealed that, at a
concentration of 70%, neither acute (Figure 3)n o rc h r o n i c
(Figures 4 and 5,a n dT a b l e1) DMSO administration
altered morphine antinociception. The main results are
illustrated in Figure 6. Although acute low-dose curcumin
did not enhance morphine’s antinociceptive action (Fig-
ure 3), it did attenuate morphine tolerance during the
treatment period (Figure 4). Acute morphine injection
followed by high-dose curcumin 15min later enhanced
the antinociceptive eﬀect of morphine when measured
15min after the injection of the last drug (Figure 3).
The eﬀect of chronic daily high-dose curcumin injections,
irrespective of whether it enhanced or preserved morphine’s
antinociception, was completely eliminated on days 5–
7( F i g u r e4). Morphine administration followed by low-
dose curcumin produced a ∼2-fold (28mgkg−1 divided by
13mgkg−1) increase in morphine-induced antinociception,
whereas morphine administration followed by high-dose
curcumin decreased morphine-induced antinociception by
∼3.5-fold (98.1mgkg−1 divided by 28mgkg−1;T a b l e1 and6 Evidence-Based Complementary and Alternative Medicine
Table 2: Relative density of expression of serum cytokines/chemokines on Day 8 after a 7-day consecutive treatment.
Cytokine/chemokine
Treatment on each day
Normal saline
(s.c.)-Normal saline (i.p.)
(n = 5)
Morphine
(s.c.)-Normal saline
(i.p.) (n = 4)
Morphine
(s.c.)-25mgkg−1
Curcumin (i.p.) (n = 4)
Morphine
(s.c.)-400mgkg−1
Curcumin (i.p.) (n = 4)
Leptin 0.33 0.29 0.34 ND
VEGF 0.32 ND 0.30 ND
VEGF R1 0.35 0.33 0.33 ND
MDC 0.31 ND 0.29 ND
Flt3-ligand 0.30 ND 0.29 ND
SCF 0.29 0.27 0.29 ND
RANTES 0.30 0.27 0.31 ND
MIP-1α 0.41 0.31 0.43 ND
MIP-3α 0.38 0.30 0.40 ND
IL-13 0.31 0.28 0.32 ND
CRG-2 0.29 0.27 0.29 ND
sTNFRII 0.40 0.30 0.39 ND
TNFα 0.30 0.27 0.30 ND
Eotaxin ND ND 0.29 0.31
Each injection was delivered in 100μL vehicles and the interval between injections administered on the same day was 15min. Abbreviations for speciﬁc
cytokines/chemokines are as follows: VEGF for vascular endothelial growth factor, VEGF R1 for vascular endothelial growth factor receptor 1, MDC for
macrophage-derived cytokine, Flt3-ligand for fms-like tyrosine kinase 3 ligand, SCF for stem cell factor, RANTES for Regulated on Activation, Normal T
Expressedand Secreted, MIP-1α formacrophageinﬂammatory protein-1α,M I P - 3 α formacrophage inﬂammatory protein-3α,IL-13 forinterleukin-13,CRG-
2 for cytokine-response gene 2, sTNFRII for soluble tumour necrosis factor receptor type II, TNFα for tumor necrosis factor α.( N D :n o td e t e c t a b l e ) .
Figure 5). As for the expression of cytokine/chemokine, no
more than 2-fold changes were found. Therefore, we will
only discuss those cytokines/chemokines for which absolute
inhibition/zero expression was found in at least one group
(Table 2).
On Day 8, morphine-tolerant mice were underweight
when compared with control animals (Mo-NS versus NS-
NS in Figure 2)—which was in agreement with a previous
report [17], where the weight lag might be due to decreased
eating and drinking behaviors, resulting from morphine
withdrawal symptoms in the periods between injections.
While a chronic daily morphine injection followed by low-
dose curcumin did not further signiﬁcantly reduce body
weight in morphine-tolerant mice, the reduction in body
weight due to high-dose curcumin treatment (Mo-400 Cur
versus Mo-NS in Figure 2) corresponds with the inhibition
of leptin expression observed in these mice (Table 2). A pre-
vious report also demonstrated that dietary curcumin could
signiﬁcantly reduce plasma leptin concentration, although
in that study body weight and food intake are not altered
[18].Eventhoughtheleptinlevelcorrelatescloselywithbody
weight maintenance [19], it is also an important measure
of body fat mass. Decreased leptin levels have been shown
to cause obesity [20]; however, it also reﬂects a decrease in
total body fat mass [19]. The latter eﬀect could reasonably
explain our observation since only a 7-day cycleof high-dose
curcumin injection after morphine was able to signiﬁcantly
reduce body weight gain compared with morphine injection
alone (Figure 2) and thereby eliminate the expression of
leptin (Table 2).
Dietary supplements with similar high-dose curcumin
(500mgkg−1 per diet) decreased body fat and body weight
gain in high-fat diet-fed mice by exerting an anti-angiogenic
eﬀect in the subcutaneous adipose tissue, in which the
expression of VEGF and its receptor VEGFR-2 were down-
regulated [21]. We screened the expression of three VEGF
receptors, and the expression of VEGFR-1, but not VEGFR-2
or VEGFR-3 (data not shown), was eliminated by high-dose
curcumin (Table 2). The discrepancy between the types of
VEGF receptors involved might be attributable to the diet
formula. While blockage of VEGFR-2 can limit fatty tissue
expansion in high-fat diet-fed mice [22], inhibition of the
VEGFR-1 signaling pathway can limit the adipose tissue in
both mice fed with a high-fat diet and standard-fat diet [23].
Therefore, the reduced leptin level reﬂected the lower total
f a tm a s si nm i c et h a tw e r ef e dw i t has t a n d a r d - f a td i e ta n d
this may be associated with an inactivated VEGF-VEGFR1
pathway during the course of the experiment.
Expression of VEGF enhances the recruitment of
endothelial progenitor cells [24] and is associated with
distant metastases and poor tumor outcomes [25]. Although
morphine has been reported to inhibit VEGF expression in
myocardial ischemia [26] and chronic morphine adminis-
tration (10mgkg−1, s.c.) for 6 days can provide relief from
cancer pain and inhibit tumor growth and metastasis in
am o u s em o d e l[ 27], so far no direct link between VEGF
and morphine tolerance has ever been reported. Our results
showed that, after a consecutive 7-day morphine treat-
ment (10mgkg−1, s.c.), VEGF expression was completely
eliminated in tolerant mice (Table 2). This provides anEvidence-Based Complementary and Alternative Medicine 7
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Figure 6: Biphasic eﬀect of curcumin on morphine tolerance. After a 7-day drug intervention, AD50 values calculated from the cumulative
dose-response curve on Day 8 showed that low-dose curcumin attenuates morphine tolerance but high-dose curcumin aggravates it.
explanation, at least in part, for why chronic morphine
treatments can reduce tumor growth and metastasis.
Proinﬂammatory cytokines and chemokines play an
important part in the development of morphine tolerance
[2, 3]. It is, therefore, not surprising that most of the
cytokines and chemokines in the morphine plus vehicle
group were comparable to the vehicle only group on Day
8( T a b l e2) since, in morphine-tolerant animals, elevation
of these proteins only appears 2 h after morphine admin-
istration and disappears 24 h later [3]. Although morphine
tolerance shares a common neuroplastic pathway with neu-
ropathicpain,ittendstoexhibitmoretransitory biochemical
alterations in response to a morphine challenge [9]. A
similar presentation can be found in the patterns of elevated
excitatory amino acid (EAA) levels in morphine-tolerant
rats. Increases in cerebrospinal ﬂuid (CSF)-EAAs, which
are partially responsible for N-methyl-D-aspartate receptor
(NMDAR) activation and therefore for the mechanism of
chronic opioid-inducedneuronaladaptation, are notpresent
during the development of morphine tolerance [28–30]
but are observed after morphine challenge or naloxone-
precipitated morphine withdrawal [31]. Conceivably, our
data suggest that, in the state of morphine tolerance,
the expression of most cytokines/chemokines does not
signiﬁcantly change and instead is maintained in another
paraphysiological balanced state.
In additiontoVEGF,there aretwoothercytokines,MDC
and Flt3-ligand, which were inhibited in morphine-tolerant
mice, recovered by low-dose curcumin and secondarily
inhibited by high-dose curcumin (Table 2). Neuronal apop-
tosis induced by prolonged exposure to morphine is associ-
atedwithmorphine tolerance[32],indicating thatmorphine
could be a neurotoxin. MDC inhibits the neuronal apoptosis
induced by the neurotoxin gp120 [33]; thus, the absence
of MDC expression on Day 8 in the morphine-vehicle
group (Table 2) might be related to morphine tolerance.
Stimulation with Flt3-ligand is associated with antiapoptosis
through the phosphorylation of the proapoptotic protein
Bad [34]. Alternatively, Flt3-ligand can act synergistically
with the nerve growth factor, which is essential for the
survival of some sensory neurons, and thereby amplify its
neurotrophic activity and increase neuronal survival [35].
Therefore, the elimination of Flt3-ligand expression might
also be related to the development of morphine tolerance in
the morphine-vehicle group. In our study, the chronic daily
injection of low-dose curcumin after morphine reversed the
inhibitive eﬀect of chronic morphine on MDC and Flt3-
ligand, an eﬀect that might be at least partly responsible for
the attenuation of morphine tolerance. However, these two
proteins were again suppressed by high-dose curcumin. Our
results demonstrate that the chronic daily injection of high-
dose curcumin after morphine not only failed to attenuate
morphine tolerance but it further worsened the condition.
Meanwhile, using protein array analysis, we found
that many other neuroprotective cytokines/chemokines are
inhibited by high-dose curcumin. SCF, which is strongly
expressed in both the developing and adult CNS, protects
neurons in vivo against apoptosis after spinal cord injury
[36], and in vitro against camptothecin-induced apoptosis
and glutamate excitotoxicity [37], which is one of the
mechanisms that cause neuropathic pain and morphine
tolerance [8]. There is evidence supporting the existence
of a β-chemokine mechanism, that acts through MIP-
1α and RANTES to contribute to neuroprotection against
the neurotoxin gp120 [38]. MIP-3α, another constitutively
expressed β-chemokine, was also shown to be suppressed in
our study by co-injection of high-dose curcumin, although
no protective eﬀects of this chemokine against neuronal
death have ever been reported. IL-13 has been shown to
protect synoviocytes [39], normal airway epithelial cells
[40] and ischemic hepatocytes [41] from apoptosis. Within
the CNS, IL-13 is expressed exclusively by microglia cells,
whose inﬂammation-induced activation can worsen CNS
damage. The mRNA level of Toll-like receptor 4 (TLR4)8 Evidence-Based Complementary and Alternative Medicine
was also found to have increased after intrathecal morphine
administration for 7 days in vivo [2]—an eﬀect which
demonstrates a signiﬁcant elevation of glial activation since
only glia express TLR4 [42]. IL-13 may also control brain
inﬂammation by inducing the death of activated microglia
in vivo, resulting in the enhancement of neuronal survival
[43]. Therefore, inhibition of IL-13 secretion by the chronic
daily injection of high-dose curcumin after morphine may
imply that the activated microglia have induced an over-
inﬂammatory state in the CNS as compared with the
morphine-vehicle group. As with IL-13, glia in the CNS
have also been reported to be one of the principal sites of
CRG-2 production in response to i.p. infection with mouse
adenovirus-type 1 [44]. We speculate that CRG-2 functions
in a way similar to IL-13, and therefore, reducing CRG-2
levels may have the potential for maintaining CNS glial cells,
despite the fact that its corresponding pro-apoptotic abilities
have only been reported in murine corneas with herpetic
stromal keratitis [45].
Previous reports demonstrated that increased TNFα
expression in the rat spinal cordis induced immediately after
a 5-day infusion of morphine and that the neuroimmune
response ispreventedwhenmorphine toleranceisattenuated
by amitriptyline [30]. However, another time-course study
revealed that the increased expression of TNFα mRNA in
the dorsal horn of the lumbar spinal cord is observed
only 2h, but not 24h, after a chronic 5-day infusion of
morphine [3]. Although we did not observe any changes in
TNFα expression 24 h after consecutive morphine injections
(Table 2), it did participate in morphine tolerance in
response to morphine. TNFα acts by binding to its two
receptors, TNFR-I and TNFR-II, with the binding aﬃnity
for the latter several-fold greater than for the former [46].
ThecleavageproductsofsTNFR-II,thesolublereceptorform
of TNFR-II, have a high aﬃnity for TNFα and therefore
retains its ability to function as a decoy binding site for this
cytokine [47, 48]. sTNFR-II has been used to treat TNFα-
mediated neuroinﬂammation [49] since it can antagonize
the activity of TNFα by sequestering the cytokine away
from the cell surface, and therefore, it can possibly lower
TNFα response to morphine. In our results, chronic co-
injection of high-dose curcumin with morphine abolished
the expression of sTNFR-II (Table 2), which could have
contributed to enhanced neuroinﬂammation in response
to morphine injection and thereby worsened morphine
tolerance.
Although morphine is immunosuppressive [50], the
eﬀects of sub-acute or chronic administration of morphine
on immune function is limited, and most immune suppres-
sion parameters are observed after drug withdrawal [51]. As
shown in our results, most proinﬂammatory cytokines, such
asIL-1,IL-6(datanotshown)andTNFαdidnotsigniﬁcantly
change 24 h after a 7-day morphine-vehicle administra-
tion or a low-dose curcumin treatment after morphine
administration, as compared with the vehicle-only control.
However, TNFα expression was inhibited by a daily injection
of high-dose curcumin after morphine for 7 days, which
could be explained by the direct dose-dependent eﬀect of
curcumin [6] or the existence of morphine withdrawal [52]
precipitated by high-dose curcumin. Tolerance to morphine
is often regarded as the gateway to the development of
physical dependence, but these two phenomena are certainly
dissociableandtheunderlyingbiochemicalmechanisms may
be diﬀerent[53].In thisstudy, we did notrecord ifmorphine
withdrawal developed on Day 8 and could not conclude
if inhibition of TNFα was associated with morphine with-
drawal. Eotaxin was neither constitutively expressed in the
vehicle-only group nor in the morphine-vehicle group but it
was induced in the curcumin-containing groups (Table 2).
However, no diﬀerence in eotaxin activation was found
between the low-dose and high-dose curcumin groups, and
therefore, it is probably not related to the biphasic eﬀect of
curcumin on morphine tolerance.
For the past several years, curcumin has been viewed as a
highly safe adjuvant for various conditions [4], and, before
our study was conducted, it had no known dose-limiting
toxicities [12]. The possibility of a biphasic behavior for
curcumin was considered because it does not only induce
cell death but also protects against it [54]. Although no
clinical evidence was available, anecdotal evidence exists for
its possible adverse eﬀects, which included DNA damage-
linked apoptotic cell death and temporal changes from an
anti-oxidant toapro-oxidant[5].Althoughapreviousreport
indicatedthatlowtomoderatedosesofcurcuminsuppressed
morphine analgesic tolerance in a dose-dependent manner,
the tail-ﬂick test was performed during a 90-min period
after morphine injection [10]. However, in ourinvestigation,
the cumulative dose-response curve and AD50 values were
calculated at 24 h after 7 days of consecutive morphine
injections. Itispossiblethattheextentofneuroinﬂammation
became more obvious at 24 h than following morphine
injection, necessitating further exploration. Our study is
the ﬁrst to demonstrate the adverse clinical eﬀects of high-
dose curcumin on morphine tolerance and the mechanism
involved in the loss of expression of neuron-protective or
antiapoptotic cytokines/chemokines, which may at least be
partly responsible for the worsening of morphine tolerance.
Our study, however, has one limitation. Although the
antibody-based protein array system oﬀers many advantages
over conventional enzyme-linked immunosorbent assays
(ELISAs), including a higher sensitivity, greater range of
detection and less variability [55], several alterations in the
expression of cytokines were found in our protein array
analysis. Therefore, it was diﬃcult to determine which one
of them is the key factor in worsening morphine tolerance.
Pinpointing a speciﬁc cause was especially diﬃcult because
this kind of alteration, where we found absolute inhibition
or zero expression, was not quantiﬁable even when repeated
with a conventional ELISA and therefore could not be
compared. Alternatively, it is possible that the cumulative
eﬀect of all the cytokine/chemokine changes is necessary to
exacerbate morphine tolerance.
In conclusion, with this cytokine/chemokine protein
array,weshowedthatwhiletheexpressionofneuroprotective
MDC and Flt3-ligand was eliminated in morphine-tolerant
mice, chronic daily injections of low-dose curcumin after
morphine administration recovered their expression and
may be, at least in part, responsible for the attenuatedEvidence-Based Complementary and Alternative Medicine 9
morphine tolerance observed in these mice. Chronic daily
injections of high-dose curcumin after morphine further
abolished the expression of other antiapoptotic cytokines
or neuroprotective factors and thereby worsened morphine
tolerance. Curcumin by itself is a neuroprotectant [14, 56],
but, as shown in our results, it might cause neurotoxicity
when given chronically in high doses with morphine. In
clinical practice, although curcumin is relatively safe to use
as a single high dose orally [12], the eﬀect of curcumin on
morphine tolerance might be biphasic and therefore should
be used cautiously.
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